"Triaging" Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies.
作者信息
Martelletti Paolo
机构信息
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
出版信息
Pain Ther. 2020 Dec;9(2):349-351. doi: 10.1007/s40122-020-00171-7. Epub 2020 Apr 30.
Abstract
摘要
相似文献
1
"Triaging" Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies.对需要降钙素基因相关肽（CGRP）单克隆抗体的慢性偏头痛患者进行“分诊”
Pain Ther. 2020 Dec;9(2):349-351. doi: 10.1007/s40122-020-00171-7. Epub 2020 Apr 30.
2
Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex.基于患者性别评估降钙素基因相关肽（CGRP）靶向疗法治疗急性和预防性偏头痛的疗效。
Cephalalgia. 2024 Mar;44(3):3331024241238153. doi: 10.1177/03331024241238153.
3
Anti-calcitonin gene-related peptide monoclonal antibodies for neuropathic pain in patients with migraine headache.抗降钙素基因相关肽单克隆抗体治疗偏头痛患者的神经病理性疼痛。
Muscle Nerve. 2021 Apr;63(4):563-567. doi: 10.1002/mus.27153. Epub 2021 Jan 8.
4
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention.阻断 CGRP 传递的单克隆抗体：在偏头痛预防中的附加价值更新。
Rev Neurol (Paris). 2020 Dec;176(10):788-803. doi: 10.1016/j.neurol.2020.04.027. Epub 2020 Aug 2.
5
Safety and Tolerability of 3 CGRP Monoclonal Antibodies in Practice: A Retrospective Cohort Study.在实践中 3 种 CGRP 单克隆抗体的安全性和耐受性：一项回顾性队列研究。
Headache. 2020 Nov;60(10):2454-2462. doi: 10.1111/head.13956. Epub 2020 Sep 23.
6
Combination of anti-CGRP/CGRP-R mAbs with onabotulinumtoxin A as a novel therapeutic approach for refractory chronic migraine: a retrospective study of real-world clinical evidence and a protocol for a double-blind, randomized clinical trial to establish the efficacy and safety.抗降钙素基因相关肽/降钙素基因相关肽受体单克隆抗体与A型肉毒毒素联合应用作为难治性慢性偏头痛的一种新型治疗方法：真实世界临床证据的回顾性研究及一项双盲、随机临床试验方案以确定其疗效和安全性
Front Pharmacol. 2023 Dec 13;14:1296577. doi: 10.3389/fphar.2023.1296577. eCollection 2023.
7
Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials.偏头痛预防性治疗的新兴药物：CGRP 单克隆抗体和 gepants 试验综述。
Expert Opin Emerg Drugs. 2023 Dec;28(2):79-96. doi: 10.1080/14728214.2023.2207819. Epub 2023 Apr 28.
8
Treatment and management of migraine in neurological ambulatory practice in Poland by indicating therapy with monoclonal anti-CGRP antibodies.在波兰的神经科门诊实践中，通过使用单克隆抗 CGRP 抗体进行治疗，对偏头痛进行治疗和管理。
Neurol Neurochir Pol. 2020;54(4):337-343. doi: 10.5603/PJNNS.a2020.0054. Epub 2020 Jul 20.
9
Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.过度警觉、应激负荷与偏头痛预防：降钙素基因相关肽（CGRP）或其受体抗体
Neurol Ther. 2021 Dec;10(2):469-497. doi: 10.1007/s40120-021-00250-7. Epub 2021 Jun 2.
10
An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.针对降钙素基因相关肽及其受体的单克隆抗体的观察性研究。
Eur J Neurol. 2023 Jun;30(6):1764-1773. doi: 10.1111/ene.15761. Epub 2023 Mar 15.
本文引用的文献
1
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine.一项关于fremanezumab治疗偏头痛的循证综述。
Pain Ther. 2020 Jun;9(1):195-215. doi: 10.1007/s40122-020-00159-3. Epub 2020 Mar 28.
2
A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches.慢性偏头痛的非处方治疗方法全面综述
Curr Pain Headache Rep. 2020 Mar 21;24(5):19. doi: 10.1007/s11916-020-00852-0.
3
Adult Migraine Hospital Admission Trends in Finland: A Nationwide Registry Study.芬兰成人偏头痛住院趋势：一项全国性登记研究
J Clin Med. 2020 Jan 23;9(2):320. doi: 10.3390/jcm9020320.
4
Acute headache management in emergency department. A narrative review.急诊科急性头痛的管理：一篇叙述性综述。
Intern Emerg Med. 2020 Jan;15(1):109-117. doi: 10.1007/s11739-019-02266-2. Epub 2020 Jan 1.
5
Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre.慢性和发作性偏头痛患者在三级头痛中心连续治疗两年的成本。
J Headache Pain. 2019 Dec 30;20(1):120. doi: 10.1186/s10194-019-1068-y.
6
The clinical and public health implications and risks of widening the definition of chronic migraine.扩大慢性偏头痛定义的临床和公共卫生意义及风险。
Cephalalgia. 2020 Apr;40(4):407-410. doi: 10.1177/0333102419895777. Epub 2019 Dec 15.
7
Burden of headache disorders in China, 1990-2017: findings from the Global Burden of Disease Study 2017.中国头痛障碍负担，1990-2017 年：2017 年全球疾病负担研究结果。
J Headache Pain. 2019 Nov 7;20(1):102. doi: 10.1186/s10194-019-1048-2.
8
Prevalence and burden of headache in children and adolescents in Austria - a nationwide study in a representative sample of pupils aged 10-18 years.奥地利儿童和青少年头痛的患病率和负担 - 10-18 岁学生代表性样本的全国性研究。
J Headache Pain. 2019 Nov 6;20(1):101. doi: 10.1186/s10194-019-1050-8.
9
Headaches in the emergency department -a survey of patients' characteristics, facts and needs.急诊科头痛患者的特征、实际情况和需求调查。
J Headache Pain. 2019 Nov 5;20(1):100. doi: 10.1186/s10194-019-1053-5.
10
Economic burden of migraine in Latvia and Lithuania: direct and indirect costs.拉脱维亚和立陶宛偏头痛的经济负担：直接和间接成本。
BMC Public Health. 2019 Sep 9;19(1):1242. doi: 10.1186/s12889-019-7461-2.
Zotero 插件